:Capravirine
{{chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 391146416
| ImageFile = capravirine.png
| ImageSize = 200px
| PIN = {5-[(3,5-Dichlorophenyl)sulfanyl]-4-(propan-2-yl)-1-[(pyridin-4-yl)methyl]-1H-imidazol-2-yl}methyl carbamate
| OtherNames =
| Section1 = {{Chembox Identifiers
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = VHC779598X
| CASNo_Ref = {{cascite|correct|??}}
| CASNo = 178979-85-6
| PubChem = 1783
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 435128
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 1717
| SMILES = O=C(OCc2nc(c(Sc1cc(Cl)cc(Cl)c1)n2Cc3ccncc3)C(C)C)N
| InChI = 1/C20H20Cl2N4O2S/c1-12(2)18-19(29-16-8-14(21)7-15(22)9-16)26(10-13-3-5-24-6-4-13)17(25-18)11-28-20(23)27/h3-9,12H,10-11H2,1-2H3,(H2,23,27)
| InChIKey = YQXCVAGCMNFUMQ-UHFFFAOYAP
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C20H20Cl2N4O2S/c1-12(2)18-19(29-16-8-14(21)7-15(22)9-16)26(10-13-3-5-24-6-4-13)17(25-18)11-28-20(23)27/h3-9,12H,10-11H2,1-2H3,(H2,23,27)
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = YQXCVAGCMNFUMQ-UHFFFAOYSA-N
}}
|Section2 = {{Chembox Properties
| Formula = C20H20Cl2N4O2S
| MolarMass = 451.37 g/mol
| Appearance =
| Density =
| MeltingPt =
| BoilingPt =
| Solubility =
}}
|Section3 = {{Chembox Hazards
| MainHazards =
| FlashPt =
| AutoignitionPt =
}}
}}
Capravirine was a non-nucleoside reverse transcriptase inhibitor which reached phase II trials before development was discontinued by Pfizer.{{Cite web|url=https://pubchem.ncbi.nlm.nih.gov/compound/1783|title=Capravirine|last=PubChem|website=pubchem.ncbi.nlm.nih.gov|language=en|access-date=2019-06-02}}{{Cite web|url=https://www.drugdevelopment-technology.com/projects/capravirine/|title=Capravirine - Anti-Retroviral Drug|website=Drug Development Technology|language=en-GB|access-date=2019-06-02}} Both phase IIb trials which were conducted failed to demonstrate that therapy with capravirine provided any significant advantage over existing triple-drug HIV therapies, and pharmacology studies showed that capravirine may interact with other HIV drugs.{{Cite web|url=https://www.drugdevelopment-technology.com/projects/capravirine/|title=Capravirine - Anti-Retroviral Drug|website=Drug Development Technology|language=en-GB|access-date=2019-06-02}}{{Cite journal|url=https://clinicaltrials.gov/ct2/show/NCT00006211|title=A Study of Capravirine Plus VIRACEPT Plus Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients Who Failed Previous Anti-HIV Treatments - Full Text View - ClinicalTrials.gov|website=clinicaltrials.gov|date=23 June 2005 |language=en|access-date=2019-06-02}}